Phaseline

Targets › RSVB

RSVB: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Jul 2028.

Open in Phaseline: the race on RSVB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiBivalent RSV+HMPV protein vaccine (RPF08203)
Respiratory syncytial virus and human metapneumovirus protein vaccine
RSVA, RSVB, HMPVPhase 2Respiratory Syncytial VirusJul 2028

Conditions

Respiratory Syncytial Virus (1)

Modalities

other (1)

Companies

Sanofi (1)

Related targets

RSVA (1) HMPV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.